Earnings Feed
Start Free
Pyxis Oncology, Inc.·4

Mar 25, 5:08 PM ET

Lewis-Hall Freda C 4

Research Summary

AI-generated summary

Updated

Pyxis Oncology (PYXS) Director Freda C. Lewis-Hall Receives Award

What Happened
Freda C. Lewis-Hall, a director of Pyxis Oncology (PYXS), received a grant of 45,867 derivative shares recorded as an award on 2026-03-24. The award was reported at a $0.00 acquisition price (typical for option/RSU grants) and has no immediate cash value; it represents compensation rather than an open‑market purchase or sale.

Key Details

  • Transaction date: 2026-03-24; Form 4 filed 2026-03-25 (timely filing).
  • Transaction type/code: Grant/Award (A); derivative securities granted.
  • Shares granted: 45,867 units; acquisition price reported as $0.00.
  • Vesting: 100% of the award vests on the first anniversary of the grant, subject to continued service (footnote F1).
  • Shares owned after transaction: Not specified in the provided excerpt of the filing.
  • No immediate sale or exercise reported; this is a compensation grant, not a cash transaction.

Context: Grants to directors are a common form of compensation and do not necessarily signal buying or selling intent. Because the award vests after one year and wasn't sold, there is no immediate market impact.